Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 11086 participants.
Also called NCT05845489
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 11,086 participants
- Sponsor
- Registry
-
NCT05845489
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT05845489. Randomized; no masking; primary purpose prevention. Start 2023-03-22 (actual); primary completion 2028-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION)
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- Clopidogrel treatment group
- Intervention (Other)
- No antiplatelet or anticoagulant group
- Lead sponsor
- Seoul National University Hospital
- Collaborator
- Samjin Pharmaceutical Co., Ltd.
- Collaborator
- CKD Pharmaceutical Limited
- Collaborator
- Hanmi Pharmaceutical co., ltd.
- Collaborator
- Yuhan Pharmaceutical Company
- Collaborator
- Daewoong Pharmaceutical Co. LTD.
- Collaborator
- Dong-A ST Co., Ltd.
- Collaborator
- IlDong Pharmaceutical Co Ltd
Record details
- Record id
cardio:ct-nct05845489- Content hash
de78243bf711578da1f6d19ca61e102e404aa8ca73d54a9330ab3c7cf1435305